Drug profile · INN
naproxen
ANAPROX 550
naproxen (ANAPROX 550) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — naproxen
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 9
- Data quality
- 0.89
Quick answer
naproxen (ANAPROX 550) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is naproxen?
naproxen (ANAPROX 550) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for naproxen?
ANAPROX 550 is a marketed brand name for naproxen. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of naproxen?
naproxen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.